Vor Biopharma Inc (VOR)

$14.53 +1.00 (7.39%)
Market Cap 140.86M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 0.05
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 850,400
Avg Vol 1,900,938
Day's Range N/A - N/A
Shares Out 10.41M
Stochastic %K 55%
Beta 2.08
Analysts Strong Sell
Price Target $40.00

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
RobinBartlett225
RobinBartlett225 Dec. 24 at 4:13 PM
$VOR Looking towards the $25 level
0 · Reply
kellyc09
kellyc09 Dec. 24 at 2:59 PM
$VOR Been waiting for this day. Stock after an upgrade and good report has moved in the wrong direction. Biotech hot today so love this move .
0 · Reply
look2hook
look2hook Dec. 24 at 2:54 PM
$VOR Gotta whale buy...
0 · Reply
tackinis
tackinis Dec. 24 at 10:57 AM
Still Holding $IOVA as I posted at $2 till $8.40 strong, Getting in to $SNTI first target $1.35, Got some $VOR and $ESHA and will get more if it's drops, also $VADP waiting till it blow up tripple, good luck trading everyone and Happy New Year!
1 · Reply
etrade
etrade Dec. 24 at 7:12 AM
$VOR you need to listen ;)
0 · Reply
jaj89
jaj89 Dec. 23 at 11:28 PM
$VOR nearly given back yesterday's gains.
0 · Reply
maynotcung
maynotcung Dec. 23 at 12:28 PM
$FJET $SIDU Every dollar stuck in a hopeless losing trade is a dollar held hostage from a winning opportunity. Stop saving the losers; free your capital for the winners. $MAAS $VOR
0 · Reply
kellyc09
kellyc09 Dec. 22 at 8:44 PM
$VOR First day it looks like it will hold on to gains. Good sign,
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 3:29 PM
$VOR
0 · Reply
GSP
GSP Dec. 22 at 12:51 PM
$RKLB $ONDS $NBY $VOR $OLMA
0 · Reply
Latest News on VOR
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Dec 23, 2025, 4:01 PM EST - 1 day ago

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

Vor Bio Announces $150 Million Private Placement

Dec 15, 2025, 8:00 AM EST - 9 days ago

Vor Bio Announces $150 Million Private Placement

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 5 weeks ago

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Nov 11, 2025, 9:43 AM EST - 6 weeks ago

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Nov 10, 2025, 9:56 PM EST - 6 weeks ago

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Nov 10, 2025, 4:01 PM EST - 6 weeks ago

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Nov 8, 2025, 11:45 AM EST - 6 weeks ago

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences

Nov 7, 2025, 8:00 AM EST - 6 weeks ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Nov 3, 2025, 8:00 AM EST - 7 weeks ago

Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 31, 2025, 4:30 PM EDT - 7 weeks ago

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Oct 29, 2025, 11:01 AM EDT - 2 months ago

Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Oct 22, 2025, 4:30 PM EDT - 2 months ago

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Oct 17, 2025, 8:00 AM EDT - 2 months ago

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Oct 16, 2025, 8:00 AM EDT - 2 months ago

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Oct 14, 2025, 8:00 AM EDT - 2 months ago

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Sep 29, 2025, 7:00 AM EDT - 3 months ago

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Sep 25, 2025, 11:48 AM EDT - 3 months ago

Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise

Vor Bio Appoints Navid Z. Khan, Ph.D.

Sep 23, 2025, 8:00 AM EDT - 3 months ago

Vor Bio Appoints Navid Z. Khan, Ph.D.

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Sep 17, 2025, 9:00 PM EDT - 3 months ago

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Sep 17, 2025, 4:15 PM EDT - 3 months ago

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 12, 2025, 4:15 PM EDT - 3 months ago

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Aug 13, 2025, 11:15 AM EDT - 4 months ago

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Aug 13, 2025, 8:30 AM EDT - 4 months ago

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Aug 4, 2025, 8:30 AM EDT - 5 months ago

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Jul 21, 2025, 8:30 AM EDT - 5 months ago

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 18, 2025, 4:00 PM EDT - 5 months ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Jul 17, 2025, 8:30 AM EDT - 5 months ago

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Jul 10, 2025, 4:00 PM EDT - 5 months ago

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 6 months ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 6 months ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 6 months ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 6 months ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 8 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 9 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 11 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 11 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 1 year ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 1 year ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 1 year ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 1 year ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 1 year ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 2 years ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

RobinBartlett225
RobinBartlett225 Dec. 24 at 4:13 PM
$VOR Looking towards the $25 level
0 · Reply
kellyc09
kellyc09 Dec. 24 at 2:59 PM
$VOR Been waiting for this day. Stock after an upgrade and good report has moved in the wrong direction. Biotech hot today so love this move .
0 · Reply
look2hook
look2hook Dec. 24 at 2:54 PM
$VOR Gotta whale buy...
0 · Reply
tackinis
tackinis Dec. 24 at 10:57 AM
Still Holding $IOVA as I posted at $2 till $8.40 strong, Getting in to $SNTI first target $1.35, Got some $VOR and $ESHA and will get more if it's drops, also $VADP waiting till it blow up tripple, good luck trading everyone and Happy New Year!
1 · Reply
etrade
etrade Dec. 24 at 7:12 AM
$VOR you need to listen ;)
0 · Reply
jaj89
jaj89 Dec. 23 at 11:28 PM
$VOR nearly given back yesterday's gains.
0 · Reply
maynotcung
maynotcung Dec. 23 at 12:28 PM
$FJET $SIDU Every dollar stuck in a hopeless losing trade is a dollar held hostage from a winning opportunity. Stop saving the losers; free your capital for the winners. $MAAS $VOR
0 · Reply
kellyc09
kellyc09 Dec. 22 at 8:44 PM
$VOR First day it looks like it will hold on to gains. Good sign,
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 22 at 3:29 PM
$VOR
0 · Reply
GSP
GSP Dec. 22 at 12:51 PM
$RKLB $ONDS $NBY $VOR $OLMA
0 · Reply
Stormfury66
Stormfury66 Dec. 22 at 12:00 AM
$VOR This stock back in June went from 5.80 .. then climbed rapidly to 32.57 In the same month .. wild swings
0 · Reply
SalBoom
SalBoom Dec. 21 at 1:57 PM
$VOR imagine one of theesedays a good news and 10x volume...easy +30%
0 · Reply
fgdsgfs
fgdsgfs Dec. 21 at 12:14 PM
$QQQ $VOR $LAZR
0 · Reply
jaj89
jaj89 Dec. 19 at 8:10 PM
$VOR Yep, 20+% down in 3 days based on nothing is nuts.
0 · Reply
kellyc09
kellyc09 Dec. 19 at 7:14 PM
$VOR This stock cannot hold gains. Maybe it’s a long term play but trading it could be frustrating .
0 · Reply
WhyMeWorry
WhyMeWorry Dec. 19 at 7:10 PM
$VOR Small Float ?
0 · Reply
jaj89
jaj89 Dec. 19 at 6:59 PM
$VOR Alright clown bot.
0 · Reply
Stormfury66
Stormfury66 Dec. 19 at 6:58 PM
$VOR Put you big boy pants on .. obviously your a newbie who has never traded bio stocks . ONE LAST TIME .. it’s a long play for me .. so STOP bothering me . I’m having a FANTASTIC day in the market
0 · Reply
jaj89
jaj89 Dec. 19 at 6:54 PM
$VOR You said 12.52, in fact, you talk a lot of utter shite.
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 4:25 PM
JP Morgan has adjusted their stance on Vor Biopharma ( $VOR ), setting the rating to Overweight with a target price of 43 → 40.
0 · Reply
Stormfury66
Stormfury66 Dec. 19 at 3:32 PM
$VOR As I posted yesterday the support is 12.42 .. when it’s dips to there I Add ..& yes RSI indicates oversold
0 · Reply
Stormfury66
Stormfury66 Dec. 19 at 3:31 PM
$VOR I waited a year with a 400% gain on CAPR .. if you don’t have the stomach for volatility , then don’t trade bio stocks GLTA
0 · Reply